Compare National Beverage Corp. (FIZZ) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs GSK plc — how do they compare? National Beverage Corp. trades at $31.72 (market cap $2.89B), while GSK plc trades at $52.44 (market cap $101.34B). The key difference: GSK plc is far larger — about 35.1× National Beverage Corp.'s market cap, and GSK plc pays a 3.49% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | GSK | |
|---|---|---|
Market Cap | $2.89B | $101.34B |
Sector | Consumer Cyclical | Health |
52-Week High | $47.69 | $61.18 |
52-Week Low | $30.85 | $36.20 |
Enterprise Value | $2.60B | $121.95B |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $31.47, up 1.78% today, but faces bearish technical signals with three consecutive earnings misses. The company maintains solid profitability with 15.56% net margins and 34.03% ROE, though revenue growth has stalled at $1.2B annually. Recent news highlights a $3.25 special dividend announcement but also concerns about LaCroix brand decline and muted growth prospects.
The outlook remains cautious with analyst sentiment skewed bearish (50% sell ratings) and technical indicators pointing downward. While the dividend provides shareholder return, fundamental challenges including competitive pressures and stagnant revenue create headwinds for meaningful price appreciation in the near term.
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
